Genital herpes infections and their related complications lead to billions of dollars in healthcare expenditures and productivity losses globally, according to the first ever global estimates of the economic costs of these conditions.
The paper, which publishes July 1st in the journal BMC Global and Public Health, calls for greater investment in prevention of herpes transmission, including concerted efforts to develop effective vaccines against this common virus.
Corresponding author Nathorn Chaiyakunapruk, PharmD, PhD, professor of pharmacotherapy, and Haeseon Lee, PharmD, research fellow in pharmacotherapy, both at the College of Pharmacy of University of Utah Health, performed the research in collaboration with the World Health Organization and other academic institutions. They detail the associated economic cost estimates for genital herpes globally and by region. The findings underscore the critical need for accelerated development of effective HSV vaccines, according to the authors. Current treatments, such as antiviral drugs, can alleviate symptoms but do not prevent transmission or recurrence of the infection. A safe and effective vaccine could significantly reduce the health and economic burden of HSV infections globally, the authors say.
It is mostly acquired in childhood, spreads by oral contact and causes infections in or around the mouth (oral herpes or cold sores). Adults can acquire genital HSV-1 infection through sexual contact if they were not infected during childhood. Type 2 spreads by sexual contact and causes genital herpes.
In addition to sores and blisters, HSV can cause other more serious complications requiring healthcare attention, including a rare chance of mother to child transmission during childbirth, and increased risk of HIV infection.
(Newswise/SSH)